IRONWOOD PHARMACEUTICALS INCIRWD
| Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Net income (loss) | -65 | -73 | - | - | - | - | -117 | -282 | 22 | 106 | 528 | 175 | -1,032 |
---|
Depreciation | - | - | - | - | - | - | - | - | 6 | 4 | 2 | 1 | 2 |
---|
Loss on disposal of property and equipment | -0 | -0 | -1 | -0 | 0 | 0 | -1 | 2 | -0 | -0 | -0 | -0 | - |
---|
Share-based Compensation | 12 | 18 | 20 | 26 | 25 | 29 | 34 | 44 | 31 | 31 | 22 | 27 | 32 |
---|
Fair Value Adjustment of Warrants | - | - | - | - | 4 | 38 | -21 | -58 | 16 | -12 | -11 | -1 | -0 |
---|
Change in fair value of convertible note hedges | - | - | - | - | 5 | -46 | 24 | 67 | -19 | 18 | 12 | 1 | - |
---|
Non-cash interest expense | - | - | 2 | 2 | 8 | 15 | 16 | 18 | 20 | 22 | 24 | 2 | 2 |
---|
Deferred income taxes | - | - | - | - | - | - | - | - | - | - | - | 66 | 73 |
---|
Acquired in-process research and development | - | - | - | - | - | - | - | - | - | - | - | - | 1,095 |
---|
Accounts receivable and related party accounts receivable, net | - | 1 | 2 | 24 | 29 | 10 | 17 | -1 | 69 | -4 | -8 | -8 | - |
---|
Accounts receivable, net | -2 | - | - | - | - | - | - | - | - | - | - | - | -1 |
---|
Prepaid expenses and other current assets | -2 | 5 | 0 | 4 | -3 | 3 | -1 | 3 | 1 | -2 | -1 | -3 | -4 |
---|
Inventory, net | - | 7 | 12 | 3 | - | - | -0 | 1 | - | -1 | - | - | - |
---|
Operating lease right-of-use assets | - | - | - | - | - | - | - | - | -14 | -1 | -1 | -1 | -1 |
---|
Operating lease right-of-use assets | - | - | - | - | - | - | - | - | -14 | -1 | -1 | -1 | -1 |
---|
Other assets | -0 | 0 | -0 | 3 | -0 | -2 | -0 | -1 | -0 | 0 | 0 | -0 | 0 |
---|
Other assets | -0 | 0 | -0 | 3 | -0 | -2 | -0 | -1 | -0 | 0 | 0 | -0 | 0 |
---|
Accounts payable and accrued expenses | 5 | 24 | -12 | 1 | -2 | 20 | -7 | 8 | -33 | -8 | -3 | -8 | 12 |
---|
Accounts payable and accrued expenses | 5 | 24 | -12 | 1 | -2 | 20 | -7 | 8 | -33 | -8 | -3 | -8 | 12 |
---|
Accrued research and development costs | -1 | -1 | -2 | 0 | 1 | 3 | 0 | 1 | -0 | -1 | 14 | -11 | -6 |
---|
Accrued research and development costs | -1 | -1 | -2 | 0 | 1 | 3 | 0 | 1 | -0 | -1 | 14 | -11 | -6 |
---|
Operating lease liabilities | - | - | - | - | - | - | - | - | -12 | 0 | -2 | -2 | -2 |
---|
Operating lease liabilities | - | - | - | - | - | - | - | - | -12 | 0 | -2 | -2 | -2 |
---|
Other liabilities | - | - | - | - | - | - | - | - | - | 1 | -1 | 11 | 1 |
---|
Deferred revenue | - | - | - | - | - | - | - | - | 1 | -1 | - | - | - |
---|
Other liabilities | - | - | - | - | - | - | - | - | - | 1 | -1 | 11 | 1 |
---|
Deferred income taxes | - | - | - | - | - | - | - | - | - | - | - | 66 | 73 |
---|
Accounts receivable and related party accounts receivable, net | - | 1 | 2 | 24 | 29 | 10 | 17 | -1 | 69 | -4 | -8 | -8 | - |
---|
Accounts receivable, net | -2 | - | - | - | - | - | - | - | - | - | - | - | -1 |
---|
Prepaid expenses and other current assets | -2 | 5 | 0 | 4 | -3 | 3 | -1 | 3 | 1 | -2 | -1 | -3 | -4 |
---|
Inventory, net | - | 7 | 12 | 3 | - | - | -0 | 1 | - | -1 | - | - | - |
---|
Operating lease right-of-use assets | - | - | - | - | - | - | - | - | -14 | -1 | -1 | -1 | -1 |
---|
Operating lease right-of-use assets | - | - | - | - | - | - | - | - | -14 | -1 | -1 | -1 | -1 |
---|
Other assets | -0 | 0 | -0 | 3 | -0 | -2 | -0 | -1 | -0 | 0 | 0 | -0 | 0 |
---|
Other assets | -0 | 0 | -0 | 3 | -0 | -2 | -0 | -1 | -0 | 0 | 0 | -0 | 0 |
---|
Accounts payable and accrued expenses | 5 | 24 | -12 | 1 | -2 | 20 | -7 | 8 | -33 | -8 | -3 | -8 | 12 |
---|
Accounts payable and accrued expenses | 5 | 24 | -12 | 1 | -2 | 20 | -7 | 8 | -33 | -8 | -3 | -8 | 12 |
---|
Accrued research and development costs | -1 | -1 | -2 | 0 | 1 | 3 | 0 | 1 | -0 | -1 | 14 | -11 | -6 |
---|
Accrued research and development costs | -1 | -1 | -2 | 0 | 1 | 3 | 0 | 1 | -0 | -1 | 14 | -11 | -6 |
---|
Operating lease liabilities | - | - | - | - | - | - | - | - | -12 | 0 | -2 | -2 | -2 |
---|
Operating lease liabilities | - | - | - | - | - | - | - | - | -12 | 0 | -2 | -2 | -2 |
---|
Other liabilities | - | - | - | - | - | - | - | - | - | 1 | -1 | 11 | 1 |
---|
Deferred revenue | - | - | - | - | - | - | - | - | 1 | -1 | - | - | - |
---|
Other liabilities | - | - | - | - | - | - | - | - | - | 1 | -1 | 11 | 1 |
---|
Net cash provided by operating activities | -75 | -70 | -273 | -156 | - | -25 | -100 | -71 | 11 | 169 | 262 | 274 | 183 |
---|
Purchases of property and equipment | 10 | 14 | 10 | 4 | 4 | 4 | 4 | 9 | 7 | 2 | 0 | 0 | 0 |
---|
Net cash used in investing activities | 115 | 30 | -101 | -57 | - | -178 | 151 | 89 | -11 | -2 | -0 | -0 | -1,026 |
---|
Acquisition of VectivBio Holding AG, net of cash acquired | - | - | - | - | - | - | - | - | - | - | - | - | 1,026 |
---|
Net cash used in investing activities | 115 | 30 | -101 | -57 | - | -178 | 151 | 89 | -11 | -2 | -0 | -0 | -1,026 |
---|
Proceeds from Stock Options Exercised | - | - | - | - | - | 25 | 26 | 32 | 14 | 19 | 20 | 10 | - |
---|
Proceeds from exercise of stock options and employee stock purchase plan | - | - | - | - | - | - | - | - | - | - | - | - | 6 |
---|
Repayment of 2022 Convertible Notes | - | - | - | - | - | - | - | - | 227 | - | - | 121 | - |
---|
Purchase of subsidiary shares from noncontrolling interests | - | - | - | - | - | - | - | - | - | - | - | - | 26 |
---|
Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | 24 | 126 | - |
---|
Repayment of 2022 Convertible Notes | - | - | - | - | - | - | - | - | 227 | - | - | 121 | - |
---|
Net cash provided by (used in) financing activities | 3 | 89 | 314 | 211 | - | -4 | 20 | 30 | -1 | 19 | -5 | -238 | 277 |
---|
Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | 24 | 126 | - |
---|
Proceeds from revolving credit facility | - | - | - | - | - | - | - | - | - | - | - | - | 400 |
---|
Costs associated with revolving credit facility | - | - | 8 | - | - | 0 | 0 | - | - | - | - | - | 3 |
---|
Repayments of revolving credit facility | - | - | - | - | - | - | - | - | - | - | - | - | 100 |
---|
Net cash provided by (used in) financing activities | 3 | 89 | 314 | 211 | - | -4 | 20 | 30 | -1 | 19 | -5 | -238 | 277 |
---|
Net increase (decrease) in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | 48 | -2 | 186 | 257 | 36 | -566 |
---|
Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | - | - | - | - | -0 |
---|
Net increase (decrease) in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | 48 | -2 | 186 | 257 | 36 | -566 |
---|
Interest Paid, Net | - | - | - | - | - | - | 20 | 18 | 18 | 7 | 7 | 6 | 14 |
---|
Income Taxes Paid, Net | 0 | - | - | - | - | - | - | - | - | 2 | 3 | 5 | 10 |
---|
Stock repurchases payable in accrued expenses | - | - | - | - | - | - | - | - | - | - | 3 | - | - |
---|
Stock option exercise proceeds receivable in other current assets | - | - | - | - | - | - | - | - | - | - | - | 2 | - |
---|
Interest Paid, Net | - | - | - | - | - | - | 20 | 18 | 18 | 7 | 7 | 6 | 14 |
---|
Income Taxes Paid, Net | 0 | - | - | - | - | - | - | - | - | 2 | 3 | 5 | 10 |
---|
Stock repurchases payable in accrued expenses | - | - | - | - | - | - | - | - | - | - | 3 | - | - |
---|
Stock option exercise proceeds receivable in other current assets | - | - | - | - | - | - | - | - | - | - | - | 2 | - |
---|